4ALBERTS DS, HANNIGAN EV, LIU PY, et al. Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: an intergroup study [ J ]. Gyneeol Oncol, 2006, 100 ( 1 ): 133-138.
5JEMAL A, SIEGEL R, WARD E, et al. Cancer statistics, 2007[ J ]. CA Cancer J Clin, 2007, 57( 1 ): 43-66.
6BLOSS J D, BRADY M F, LIAO S Y, et al. Extraovarian peritoneal serous papillary carcinoma: a phase II trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma-a Gynecologic Oncology Group Study [ J ] .Gynecol Oncol, 2003, 89( 1 ): 148-154.
7FU X, HOFFMAN R M. Human ovarian carcinoma metastatic models constructed in nude mice by orthotopic transplantation of histologicallyintact patient specimens [ J ]. Anticancer Res, 1993, 13 ( 2 ): 283-286.
8WALKER W, GALLAGHER G. The development of a novel immunotherapy model of human ovarian cancer in human PBL-severe combined immunedeficient ( SCID ) mice [ J ]. Clin Exp Immunol, 1995, 101( 3 ): 494-501.
9KATO T, NISHIDA T, SUGIYAMA T, et al. Studies on experimental formation of ovarian tumors.Especially, the discussion of the developing process of ovarian tumors following an application of DMBA [ J ]. Kurume Med J, 1975, 22: 169-176.
10Kohn DB, Sadelain M, Glorioso JC. Occurrence of leukaemia following gene therapy of X-linked SCID. Nat Rev Cancer,2003,3:477-488.
